Fox Run Management L.L.C. Acquires Shares of 25,708 Travere Therapeutics, Inc. (NASDAQ:TVTX)

Fox Run Management L.L.C. bought a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the 4th quarter, HoldingsChannel reports. The firm bought 25,708 shares of the company’s stock, valued at approximately $448,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. R Squared Ltd purchased a new position in Travere Therapeutics in the 4th quarter valued at about $53,000. Quarry LP acquired a new position in shares of Travere Therapeutics during the third quarter valued at approximately $105,000. Victory Capital Management Inc. purchased a new position in shares of Travere Therapeutics in the fourth quarter valued at approximately $182,000. Baader Bank Aktiengesellschaft acquired a new position in Travere Therapeutics in the 4th quarter valued at $192,000. Finally, Entropy Technologies LP purchased a new position in Travere Therapeutics in the 4th quarter valued at $214,000.

Insiders Place Their Bets

In related news, SVP William E. Rote sold 5,200 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now owns 98,519 shares in the company, valued at approximately $2,318,152.07. The trade was a 5.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. This represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 206,335 shares of company stock worth $4,453,012 over the last ninety days. Corporate insiders own 3.75% of the company’s stock.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $21.01 on Wednesday. The firm has a market cap of $1.86 billion, a PE ratio of -5.12 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $25.29. The business’s fifty day simple moving average is $20.64 and its 200-day simple moving average is $18.37.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Equities analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TVTX has been the subject of a number of research reports. HC Wainwright upped their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Evercore ISI raised their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. Finally, Citigroup increased their price target on Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $30.62.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.